康柏西普玻璃体腔注射联合选择性激光光凝对CRVO的疗效及安全性观察

目的：探究康柏西普玻璃体腔注射联合选择性激光光凝对中央视网膜静脉阻塞(CRVO)的疗效及安全性。

方法：采用回顾性研究方法对我院眼科66例66眼CRVO患者进行研究，其中30例患者仅接受康柏西普玻璃体腔注射(对照组)，另外36例在此基础上联合选择性激光光凝治疗(观察组)。比较两组患者治疗后黄斑中心凹视网膜厚度(CMT)、BCVA和并发症发生率等差异。

结果：两组患者治疗后患眼CMT、BCVA较治疗前均得到显著改善(P<0.05)，治疗后 6mo观察组患者CMT、BCVA优于对照组(P<0.05)。观察组患者康柏西普玻璃体腔注射次数少于对照组(P<0.05)，并发症发生率组间无差异(P>0.05)。

结论：联合治疗方案对CRVO疗效更加显著，且安全性良好。

Therapeutic effect and safety of conbercept intravitreal injection combined with selective laser photocoagulation on CRVO

AIM: To investigate the efficacy and safety of conbercept intravitreal injection combined with selective laser photocoagulation for central retinal vein occlusion(CRVO).

METHODS: A retrospective study was performed on 66 patients with CRVO in our department of ophthalmology. Among them, 30 patients received only conbercept''s intravitreal injection and served as a control group. On this basis, another 36 patients were combined with selective laser photocoagulation and as an observation group. The differences of central macular thickness(CMT), BCVA(LogMAR)and complication rate after treatment were compared between the two groups.

RESULTS:The CMT and BCVA of the two groups were significantly improved after treatment(P<0.05). The CMT and BCVA of the observation group were significantly better than the control group at 6^th month after treatment(P<0.05). The number of intravitreal injections in the observation group was significantly lower than that in the control group(P<0.05). There was no significant difference in the complications(P>0.05).

CONCLUSION: The combination therapy has a more significant effect on CRVO and is safe.